Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders
Multiple Sclerosis, Chronic Pain, Neurological Disorder
About this trial
This is an interventional treatment trial for Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria:
- 18-79 years of age
- Has been diagnosed by a clinician as having MS
- Able to commit to the designated period of testing
- Able to understand the informed consent process and provide consent to participate in the study
- Capacity to complete study procedures as determined by screening personnel
- A Brief Pain Inventory interference score of at least 3 or more.
- SDMT Z-Score > -3.0
- WRAT4 Standard Score > or = 85
Exclusion Criteria:
- Visual, auditory, and motor deficits that would prevent full ability to understand study
- Visual, auditory, and motor deficits that would prevent full ability to operate VR equipment
- Uncontrolled epilepsy
- Current diagnosis of vertigo
- Uncontrolled mood disorders
- History of Psychosis or Schizophrenia
- Expanded Disability Status Scale (EDSS) Score greater than 6.5
- Unable to tolerate or manipulate VR treatment procedures (as evidenced by VR capability assessment)
Sites / Locations
- New York University School of Medicine
Arms of the Study
Arm 1
Experimental
People with Multiple Sclerosis (PwMS) and Chronic Pain
Participants with MS will only be able to receive eight treatment sessions in this study group and will complete their treatment over four weeks. Two treatments sessions must be completed each week (of the four weeks) and separated by at least one day. Participants will attend a baseline visit with assessment and training procedures and receive their first treatment immediately after all baseline assessments. Participants will then complete the remaining seven treatment sessions over four weeks. At the final treatment session, participants will repeat assessments. One week following the final treatment session, participants will be asked to return to clinic to complete assessments once more to test cumulative benefits one week following treatment end.